Screen for colon cancer with just a blood test.

  • Shield is Medicare covered.
  • $0 Out-of-pocket cost for eligible Medicare Part-B patients*
  • Shield is also covered for patients receiving Community Care, authorized by the Veterans Health Administration, and TRICARE.
Coverage
  • Shield is Medicare covered.
  • $0 Out-of-pocket cost for eligible Medicare Part-B patients*
  • Shield is also covered for patients receiving Community Care, authorized by the Veterans Health Administration, and TRICARE.

Screen for colon cancer the more pleasant way.

  • Just a blood test

  • Sample collected in minutes

“The convenience of Shield makes it a no-brainer.”

—Dennis Barnes,

Father, husband, screened with Shield

*Dennis is a paid spokesperson of Guardant Health

Is Shield right for you?

When screening for colon cancer, you have options, including colonoscopy, stool-based tests, and the Shield™ blood test. To help determine if Shield is right for you, check out this Patient Fact Sheet or talk to your doctor.

Are you between 45–85 years old?

Are you at average risk for colon cancer?

Not sure how to answer?

Answer "Yes" if you have:

  • No prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease
  • No personal diagnosis or family history of colorectal cancer or known genetic disorders such as Lynch syndrome or familial adenomatous polyposis

Are you due for colon cancer screening?

Not sure how to answer?

Answer “No,” if you’ve completed any of the following screening tests:

  • Colonoscopy within the last 10 years

Or either of the following stool tests:

  • FIT/FOBT — in the last year
  • FIT-DNA — in the last 1-3 years
Next

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is intended for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stages II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not intended for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Patient Fact Sheet for complete product information about the Shield test including full safety information.

Shield is available by Rx only.

*Medicare Advantage patients may be subject to co-pays, co-insurances, and deductibles, depending on their specific plan.

  1. References:
  2. Chung DC, Gray DM II, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973983. doi:10.1056/NEJMoa2304714 2. Shield™ Provider Brochure. Redwood City, CA: Guardant Health, 2024